Sequential Administration of Rituximab and Cladribine may Reduce Toxicity and Improve Response in Hairy Cell Leukemia

M. Heizmann¹, W. A. Wuillemin², M. Wernli¹, M. J. Bargetzi¹ (¹Aarau; ²Luzern)

Azole-induced syndrome of inappropriate antidiuresis (SIAD) in a patient with acute myeloid leukemia

K. Casauro¹, C. Schmid¹, A. Jetter¹, G. Nair¹, U. Schanz¹, G. Stüssi¹ (¹Zürich)

Risk factors leading to ICU admission after allogeneic hematopoietic stem cell transplantation and outcome of the admitted patients

R. Benz¹, U. Schanz², M. Maggiorini², J. D. Seebach³, G. Stüssi² (¹Münsterlingen; ²Zürich; ³Genève)

Resultate der Behandlung der akuten myeloischen Leukämie (AML) in der Zentralschweiz

N. G. Massali¹, W. A. Wuillemin¹, M. Gregor¹ (¹Luzern)

Chronic Neutrophilic Leukemia. A Case Report of a Rare Diagnosis

S. Isik¹, U. Lüthi¹, P. Fernandez¹, M. J. Bargetzi¹, M. Heizmann¹ (¹Aarau)

Successful use of Midostaurin in a patient with myeloid and lymphoid neoplasm with FGFR1 abnormalities

P. Beris (Genève)

The tardy evil – a case of an acute monoblastic leukemia with t(9;11)(p22;q23) and 8, preceded by a transient bicytopenia

T. Silzle¹, E. Mueller¹, J. Tchinda², P. Keller¹ (¹Bern; ²Zürich)

A single institution experience regarding the outcome of patients with mutations of nucleophosmin (NPM1) in acute myeloid leukemia

G. Nair (Zürich)

Ex vivo purging of autologous hematopoietic stem cell graft with MegaFasL

A. Nahimana¹, D. Aubry¹, L. Lagopoulos¹, P. Greaney¹, A. Attinger¹, S. Demotz¹, K. M. Dawson¹, M. Schapira¹, J. Tschopp¹, M. Dupuis¹, M. A. Duchosal¹ (¹Lausanne)

Feasibility of Therapeutic Drug Monitoring (TDM) for Imatinib: Preliminary considerations on the dosage adjustment approach for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study

V. Gotta¹, N. Widmer¹, C. Csajka¹, L. A. Decosterd¹, M. A. Duchosal¹, Y. Chalandon², M. Gregor³, D. Heim⁴, T. Buclin¹ (¹Lausanne; ²Genève; ³Luzern; ⁴Basel)

Imatinib-related non fatal liver necrosis in a patient with CML: a case report of successful second line treatment with nilotinib after liver recovery and CML relapse

V. Spataro (Bellinzona)

Omacetaxin as effective and safe treatment over 12 months in a patient with chronic myeloid leukemia (CML) with T315I mutation and osteomyelofibrosis (OMF)

C. Caspar¹, H. Schwarb¹, R. Woelky¹, E. Oppliger Leibundgut² (¹Baden; ²Bern)

Blindness in a patient with chronic lymphocytic leukemia

G. Colucci¹, J. D. Studt¹, M. Solenthaler¹, K. Ackermann¹, W. Z'graggen¹ (¹Bern)

Fatal disseminated Rhizomucor miehei infection in a patient with acute myelogenous leukemia

G. Nair¹, K. Lucke¹, E. Schwarz¹, U. Schanz¹, M. Maggiorini¹, G. Stüssi¹, M. Schneemann¹ (¹Zürich)

Trisomy 21 due to an isochromosome 21 as the sole acquired karyotypic abnormality in primary myelofibrosis with the JAK2 V617F mutation

A. Rüfer¹, L. Suda¹, M. J. Bargetzi¹, M. Wernli¹, A. R. Huber¹, B. Röthlisberger¹ (¹Aarau)

Spontane Remission eines schweren Hämophagozytose-Syndroms

A. Breitenstein¹, K. Casauro¹, H. P. Schäfer², V. Kaplan¹ (¹Zürich; ²Schaffhausen)

Cotrimoxazole (Bactrim) Myelotoxicity in Hematology Patients. Does it exist?

A. Fontanet¹, Y. Chalandon², E. Roosnek², B. Mohty², J. Passweg² (¹Chêne Bougeries; ²Genève)

Persistent CD4/CD8 double positive T-cell population after renal transplantation

K. D. Arn (Zürich)

Sustained Remission of Pure Red Cell Aplasia in a Patient with Multiple Myeloma after Induction with Bortezomib/Dexamethason and High Dose Melphalan with Autologous Stem Cell Transplantation

M. Heizmann¹, M. Stern², M. Wernli¹, M. J. Bargetzi¹ (¹Aarau; ²Basel)

Hereditary hyperferritinaemia-cataract syndrome (HHCS) presenting with iron deficiency anaemia and the identification of a new and pathogenetic relevant heterozygous mutation +24T>C (=HGVS c.-176T>C) in the iron responsive element of the L ferritin gene in a swiss family

A. Rüfer¹, J. P. Howell¹, A. P. Lange¹, R. Yamamoto², J. Heuscher¹, M. Gregor¹, W. A. Wuillemin¹ (¹Luzern; ²Dortmund DE)

Pernicious anemia with high measured vitamin B12 serum concentration

E. Levrat¹, M. Nagy-Hulliger¹, K. Gariani¹, J. Passweg¹, O. Golaz¹, P. Lescuyer¹, P. A. Pilotto¹ (¹Genève)

Prävalenz und Behandlungsmuster der chronischen Immunthrombozytopenie (ITP) in der Schweiz

U. Mey¹, T. Schaufler² (¹Chur; ²Zug)

Application of a commercially available competitive immunoassay to hepcidin quantification: what does it bring to clinical hematology?

S. Waldvogel¹, G. Canellini¹, N. Lyon¹, B. Favrat², J. D. Tissot¹, A. Angelillo-Scherrer² (¹Epalinges; ²Lausanne)

Thrombopenia, asplenia, miosis, hypocalcemia, muscle defect – congenital Stormorken’s Syndrome in a 52 year old male?

T. Lehmann¹, A. Tichelli¹, D. A. Tsakiris¹, D. Berger¹, J. P. Sigle¹ (¹Basel)

Erhöhte Inzidenz maligner hämatologischer Erkrankungen bei Blutspendern mit positivem Direktem Antiglobulintest (DAT)

A. Enekwe¹, J. Thierbach², B. Ziegler², B. M. Frey¹ (¹Schlieren; ²St. Gallen)

Optimizing collection quality and efficacy for high yield plateletpheresis in the planification of a clinical trial

S. Fontana¹, R. Summermatter¹, R. Gerber¹, M. Vogt¹, B. Mansouri Taleghani¹, D. Barmettler², P. Aegerter², J. M. Payrat² (¹Bern; ²Fenwal Europe)

Non nominal components of immunoglobulin preparations

K. Matozan¹, J. N. Han², L. Risch³, U. Nydegger⁴ (¹Bern; ²Pjongjang; ³Liebefeld; ⁴Lachen)

Transfusion reaction due to coldagglutinins in a patient with Malaria

J. P. Sigle¹, T. Boldanova¹, U. Flückiger¹, L. Infanti¹, T. Rüfli¹, H. Hustinx², A. Buser¹ (¹Basel; ²Bern)

TRALI-safe platelets: An evaluation of preventive measures to reduce the risk of TRALI after transfusion of single donor apheresis platelets in Switzerland

S. Fontana¹, J. Thierbach², M. Muriset¹, J. Sigle², P. Gowland¹, C. Niederhauser¹, K. Sunic², L. Infanti², A. Buser² (¹Bern; ²Basel)

Langzeitantikoagulation mit Fondaparinux bei einem Patienten mit mechanischer Aortenklappe

M. Nagler¹, M. Redondo¹, W. A. Wuillemin¹ (¹Luzern)

Acquired Von Willebrand Syndrome – a case report and validation of a commercial VWF Propeptide Assay (PP:AG)

M. Berger¹, C. Güthner¹, M. S. Leikauf¹, L. M. Asmis¹ (¹Zürich)

Influence of 10 mg Rivaroxaban on coagulation tests in 20 male individuals evaluated in an inter-laboratory setting (RivaMoS study group)

W. A. Wuillemin¹, L. M. Asmis², L. A. Alberio³, A. Angelillo-Scherrer⁴, U. Heimgartner², W. Korte⁵, A. Mendez⁶, G. Reber⁷, H. Stricker⁸, D. A. Tsakiris⁹ (¹Luzern; ²Zürich; ³Bern; ⁴Lausanne; ⁵St. Gallen; ⁶Aarau; ⁷Genève; ⁸Locarno; ⁹Basel)

Massive muscle hematoma two months after starting oral anticoagulant therapy

M. Jahns¹, D. Friess¹, F. Demarmels Biasiutti¹, G. Colucci¹, J. A. Kremer Hovinga¹, L. A. Alberio¹, J. Oldenburg², B. Lämmle¹ (¹Bern; ²Bonn)

Persistence of acquired von Willebrand factor deficiency after autologous stem cell transplantation for multiple myeloma

F. Boehlen¹, R. Kridel¹, J. Robert¹, Y. Tirefort¹, L. Favet¹, G. Reber¹, P. Y. Dietrich¹, P. De Moerloose¹ (¹Genève)

Acquired factor XIII inhibitor: a therapeutic challenge

F. Boehlen¹, C. Chizzolini¹, T. Koessler¹, T. Matthes¹, E. Ortner², M. Blondon¹, Y. Tirefort¹, B. Mansouri Taleghani², G. Reber¹, P. De Moerloose¹ (¹Genève; ²Bern)

Acquired transient factor V inhibitor after liver transplantation

F. Boehlen¹, I. Morard¹, T. Berney¹, J. Villard¹, G. Reber¹, P. De Moerloose¹ (¹Genève)

Acenocoumarol resistance due to a new VKORC1 mutation and possible alcohol interaction

F. Boehlen¹, K. Ing Lorenzini¹, Y. Daali¹, M. Rebsamen¹, Y. Tirefort¹, H. Robert-Ebadi¹, J. Desmeules¹, P. De Moerloose¹ (¹Genève)

Delayed-onset heparin-induced thrombocytopenia after autologous hematopoietic stem cell transplantation due to heparin flushes

E. Bianchi¹, C. Plancherel Levy², A. Rosselet¹, M. A. Duchosal¹, M. Genoud¹, A. Angelillo-Scherrer¹, S. Schmidt¹, J. M. Corpataux¹ (¹Lausanne; ²Fribourg)

Thrombolysis with rtPA and Single Shot Low Dose Substitution with Hemate in an Acute Stroke Patient with Von Willebrand Disease and a Swiss Survey on Thromboembolic Events in Hemophilia and Von Willebrand Disease

X. I. Pachmann¹, S. C. Meyer¹, A. Ehrentraut¹, H. R. Schmid¹, L. A. Alberio², L. M. Asmis³, F. Boehlen⁴, P. Lyrer⁵, C. Reutter⁶, D. A. Tsakiris⁵, J. H. Beer¹ (¹Baden; ²Bern; ³Zürich; ⁴Genève; ⁵Basel; ⁶Zurzach)

Cardiogenic shock but not acute myocardial infarction by itself activates intravascular coagulation and endogenous fibrinolysis

C. Bianda¹, G. Vassalli¹, I. D'angeli¹, I. Sulzer², G. Pedrazzini¹, T. Moccetti¹, L. A. Alberio² (¹Lugano; ²Bern)

Analytical and clinical performance of a new, semi quantitative assay panel for the diagnosis of antiphospholipid syndrome

P. De Moerloose¹, J. Arnout², G. Reber¹, J. Musial³ (¹Genève; ²Belgique; ³Pologne)

Successful Treatment of Chronic Gastrointestinal Bleeding under oral Anticoagulation with Bevacizumab

M. J. Bargetzi¹, M. Heizmann¹, M. Wernli¹ (¹Aarau)

Atypical hemolytic uremic syndrome treated with eculizumab - a case report

L. Kopfstein¹, D. Friess¹, J. A. Kremer Hovinga¹, M. Solenthaler¹, M. Gugger¹, F. Demarmels Biasiutti¹, B. Lämmle¹ (¹Bern)

Koronarthrombose mit Myokardinfarkt durch eine paroxysmale nächtliche Hämoglobinurie (PNH)

T. Kyburz¹, N. Brandenburg¹, P. O. Bonetti¹, B. Gerber², G. Stüssi², W. H. Reinhart¹ (¹Chur; ²Zürich)

Characteristics of platelet function in stable aspirin-treated cardiovascular patients

P. Fontana (Genève)

STA® NEOPLASTIN® R versus DADE® INNOVIN®: a two ISI≈1.0 Human Recombinant Thromboplastin Reagents Comparison, using the STA®-R Analyzer

D. Siciliano¹, G. Fages², A. Monn¹, H. Honegger¹ (¹Zürich; ²Asnières sur Seine )